80 related articles for article (PubMed ID: 34937801)
41. Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB-201.
Zhang M; Lei Z; Yu Z; Yao X; Li H; Xu M; Liu D
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):941-952. PubMed ID: 37078371
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
Jacobs TG; Marzolini C; Back DJ; Burger DM
J Antimicrob Chemother; 2022 Feb; 77(3):568-573. PubMed ID: 34791318
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.
Tuloup V; Goutelle S; Tod M; Bourguignon L
Clin Pharmacokinet; 2023 Feb; 62(2):307-319. PubMed ID: 36631686
[TBL] [Abstract][Full Text] [Related]
44. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
Gomez-Mantilla JD; Huang F; Peters SA
Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.
Hao J; Beck J; Zhou X; Lackner GL; Johnston R; Reinhard M; Goldsmith P; Hollinshead S; Dehlinger V; Filla SA; Wang XS; Richardson J; Posada M; Mohutsky M; Schober D; Katner JS; Chen Q; Hu B; Remick DM; Coates DA; Mathes BM; Hawk MK; Svensson KA; Hembre E
J Med Chem; 2022 Mar; 65(5):3786-3797. PubMed ID: 35175768
[TBL] [Abstract][Full Text] [Related]
46. Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Vugmeyster Y; Locke G; Helwig C; Rolfe PA; Dong JQ; Venkatakrishnan K
Clin Transl Sci; 2022 Dec; 15(12):2838-2843. PubMed ID: 36152313
[TBL] [Abstract][Full Text] [Related]
47. Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies.
Dunvald AD; Iversen DB; Svendsen ALO; Agergaard K; Kuhlmann IB; Mortensen C; Andersen NE; Järvinen E; Stage TB
Clin Transl Sci; 2022 Aug; 15(8):1856-1866. PubMed ID: 35570335
[TBL] [Abstract][Full Text] [Related]
48. Rationally Engineered CYP3A4 Fluorogenic Substrates for Functional Imaging Analysis and Drug-Drug Interaction Studies.
He RJ; Tian ZH; Huang J; Sun MR; Wei F; Li CY; Zeng HR; Zhang F; Guan XQ; Feng Y; Meng XM; Yang H; Ge GB
J Med Chem; 2023 May; 66(10):6743-6755. PubMed ID: 37145039
[TBL] [Abstract][Full Text] [Related]
49. Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT
Pusalkar S; Chowdhury SK; Czerniak R; Zhu X; Li Y; Balani SK; Ramsden D
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):371-386. PubMed ID: 35157234
[TBL] [Abstract][Full Text] [Related]
50. In Vitro Evaluation of Drug-Drug Interaction Potential of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor.
Shafiee A; Chanda S
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256953
[TBL] [Abstract][Full Text] [Related]
51. Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments.
Santamaria F; Roberto M; Buccilli D; Civita MAD; Giancontieri P; Maltese G; Nicolella F; Torchia A; Scagnoli S; Pisegna S; Barchiesi G; Speranza I; Botticelli A; Santini D
Crit Rev Oncol Hematol; 2024 Jun; ():104405. PubMed ID: 38838928
[TBL] [Abstract][Full Text] [Related]
52. Prediction of metabolizing enzyme-mediated clinical drug interactions using
Choi S; Yim DS; Bae SH
Transl Clin Pharmacol; 2022 Mar; 30(1):1-12. PubMed ID: 35419310
[TBL] [Abstract][Full Text] [Related]
53. Correction to "Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution".
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; ():. PubMed ID: 38845389
[No Abstract] [Full Text] [Related]
54. Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38438807
[No Abstract] [Full Text] [Related]
55. Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.
Kabir M; Padilha EC; Shah P; Huang R; Sakamuru S; Gonzalez E; Ye L; Hu X; Henderson MJ; Xia M; Xu X
Front Pharmacol; 2022; 13():899536. PubMed ID: 35847040
[TBL] [Abstract][Full Text] [Related]
56. Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Umehara K; Cleary Y; Fowler S; Parrott N; Tuerck D
Drug Metab Dispos; 2022 Mar; 50(3):214-223. PubMed ID: 34937801
[TBL] [Abstract][Full Text] [Related]
57. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
58. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
59. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
60. Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction.
Le Corvaisier C; Capelle A; France M; Bourguignon L; Tod M; Goutelle S
Fundam Clin Pharmacol; 2021 Apr; 35(2):208-216. PubMed ID: 32813881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
